Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity
Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a…